Search Orphan Drug Designations and Approvals
-
Generic Name: | antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads |
---|---|
Date Designated: | 10/10/2018 |
Orphan Designation: | Treatment of multiple myeloma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Sutro Biopharma, Inc. 111 Oyster Point South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-